CARA - Cara Therapeutics Inc Stock Price, Fair Value and News

0.37USD0.00 (0.00%)Market Closed

Market Summary

USD0.370.00

Market Closed

0.00%

CARA Stock Price

View Fullscreen

CARA RSI Chart

CARA Valuation

Market Cap

20.2M

Price/Earnings (Trailing)

-0.17

Price/Sales (Trailing)

1.19

EV/EBITDA

0.37

Price/Free Cashflow

-0.21

CARA Price/Sales (Trailing)

CARA Profitability

EBT Margin

-504.63%

Return on Equity

-411.18%

Return on Assets

-136.01%

Free Cashflow Yield

-485.69%

CARA Fundamentals

CARA Revenue

Revenue (TTM)

16.9M

Rev. Growth (Yr)

-65.37%

Rev. Growth (Qtr)

-28.93%

CARA Earnings

Earnings (TTM)

-122.5M

Earnings Growth (Yr)

-15.12%

Earnings Growth (Qtr)

5.07%

Breaking Down CARA Revenue

Last 7 days

8.8%

Last 30 days

27.6%

Last 90 days

-45.6%

Trailing 12 Months

-88.0%

How does CARA drawdown profile look like?

CARA Financial Health

Current Ratio

5.38

CARA Investor Care

Shares Dilution (1Y)

1.28%

Diluted EPS (TTM)

-2.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	16.9M	0	0	0
2023	43.2M	27.2M	21.2M	21.0M
2022	36.0M	48.9M	39.4M	41.9M
2021	107.1M	79.1M	51.0M	23.0M
2020	23.6M	24.0M	27.5M	135.1M
2019	17.9M	20.2M	20.9M	19.9M
2018	0	2.9M	7.9M	13.5M
2017	361.0K	636.0K	911.0K	911.0K
2016	0	2.6M	1.3M	86.0K
2015	3.5M	3.4M	4.7M	3.8M
2014	9.8M	7.6M	5.4M	3.2M
2013	0	4.8M	8.4M	12.0M
2012	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Cara Therapeutics Inc

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.

CEO	Mr. Christopher A. Posner
WEBSITE	caratherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	106

Cara Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Cara Therapeutics Inc? What does CARA stand for in stocks?

CARA is the stock ticker symbol of Cara Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cara Therapeutics Inc (CARA)?

As of Fri Jul 26 2024, market cap of Cara Therapeutics Inc is 20.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CARA stock?

You can check CARA's fair value in chart for subscribers.

Is Cara Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CARA is over valued or under valued. Whether Cara Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cara Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CARA.

What is Cara Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, CARA's PE ratio (Price to Earnings) is -0.17 and Price to Sales (PS) ratio is 1.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CARA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cara Therapeutics Inc's stock?

In the past 10 years, Cara Therapeutics Inc has provided -0.303 (multiply by 100 for percentage) rate of return.